Neumora Therapeutics, Inc. Share Price & Technical Analysis
NMRA · $1.85 (0.00%)
Healthcare / Biotechnology
$1.85
0.00%
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disor…
Price chart
Seasonality
May has 1 positive and 2 negative years (last 4 years shown)
-24% return in May, -2% avg return in past 3 year May month.
59% return in 2026, 16% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 11% | 75% | -29% | 25% | -24% | – | – | – | – | – | – | – | 59% |
| 25 | 0% | -16% | -37% | -20% | -12% | 0% | 150% | -11% | 6% | 67% | -27% | -28% | 72% |
| 24 | -13% | 18% | -22% | -35% | 9% | -2% | 29% | -11% | 17% | -17% | -15% | 7% | -35% |
| 23 | – | – | – | – | – | – | – | – | -17% | -24% | 13% | 39% | 11% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$342.78M
P/E ratio
—
52W high
$3.65
52W low
$0.66
Volume
13,62,275
Beta
3.05
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Neumora Therapeutics, Inc. share price today?
- Neumora Therapeutics, Inc. (NMRA) last traded around $1.85 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NMRA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NMRA. Download the app for real-time alerts.
- How can I analyze Neumora Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.